Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569541 | 0.89 | IDO1 (0.47) | ALDH1A1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL16729555 | 0.85 | ALDH1A1 (0.45) | ALDH1A1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL14438263 | 0.83 | CYP3A4 (0.43) | ALDH1A1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL12765145 | 0.82 | NOS1 (0.43) | HTR2ASLC6A4TACR1IDO1RAPGEF4 | |
| SCHEMBL24229573 | 0.81 | ALDH1A1 (0.41) | ALDH1A1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL18252812 | 0.81 | KCNH2 (0.44) | ALDH1A1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL12312589 | 0.81 | ALDH1A1 (0.40) | ALDH1A1SIGMAR1TACR1 | |
| SCHEMBL19443084 | 0.80 | RAPGEF4 (0.41) | HTR2ASLC6A4TACR1IDO1RAPGEF4 | |
| SCHEMBL13461889 | 0.80 | TACR1 (0.50) | MAPTTACR1IDO1RAPGEF4NOS3 | |
| Hydrochloric Acid SCHEMBL1000492 | 0.80 | ALDH1A1 (0.40) | ALDH1A1HTR2AHTR2BSIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CHEMOCENTRYX, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-11 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209573-A1 | METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS | CCR2, CXCR2, CCRL2 | ALDH1A1 3105/4885HTR2A 917/4885HTR2B 1773/4885 |
| US-11154556-B2 | Methods of treating solid tumors with CCR2 antagonists | CCR2, CXCR2, CCRL2 | ALDH1A1 3105/4885HTR2A 917/4885HTR2B 1773/4885 |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | ALDH1A1 1316/4885HTR2A 348/4885HTR2B 476/4885 |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | ALDH1A1 2065/4885HTR2A 4740/4885HTR2B 4572/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | ALDH1A1 1295/4885HTR2A 1028/4885HTR2B 1799/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | ALDH1A1 1533/4885HTR2A 835/4885HTR2B 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.